Ask AI
ProCE Banner Activity

Advances in Metastatic Castration-Resistant Prostate Cancer: Biomarker-Driven Treatment Strategies and Emerging Therapeutic Approaches

Slideset

Download this slideset on advanced prostate cancer and mCRPC to review biomarker-guided treatment selection, sequencing considerations, radiopharmaceutical strategies, and emerging investigational approaches targeting resistance mechanisms such as EZH2, CYP11A1, AR degradation, PI3K/AKT signaling, and immune pathways.

Released: July 20, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This activity is intended for oncologists, urologists, and other healthcare professionals caring for patients with prostate cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the biologic rationale for novel mechanistic targets driving resistance in mCRPC, including androgen receptor (AR) protein degradation

  • Interpret key clinical trial data for investigational agents targeting EZH2, CYP11A1, AR degradation, PI3K-AKT-mTOR, and immune pathways

  • Apply clinical evidence to patient-specific decision-making and trial referral in advanced prostate cancer